Top 10 AI Prompts and Use Cases and in the Healthcare Industry in France

France's 2023–2027 Digital Healthcare Roadmap casts AI and telehealth as practical tools to boost prevention, widen access and free clinicians from repetitive tasks - anchored by Mon espace santé, the ANS doctrine and new programmes like the PEPR and AIS under France 2030.

This state-led, ethics‑forward approach pairs strong public financing and regulation with an industrial push: from telemonitoring now reimbursed in common law to a 20,000 m² PariSanté Campus south of Paris that blends public research, startups and industry into a single innovation hub.

For healthtech builders and clinicians alike, the emphasis is clear - scale interoperable, secure solutions that preserve human oversight while meeting evolving EU rules - see the official Digital Health Roadmap and a broad overview of France's e‑health strategy for details.

Bootcamp	Length	Early bird cost	Register
AI Essentials for Work	15 Weeks	$3,582	AI Essentials for Work bootcamp - Register
Solo AI Tech Entrepreneur	30 Weeks	$4,776	Solo AI Tech Entrepreneur bootcamp - Register
Cybersecurity Fundamentals	15 Weeks	$2,124	Cybersecurity Fundamentals bootcamp - Register

“Putting digital technology to work for health.”

To build a France‑ready PEPR Digital Health evidence brief, the selection approach leaned on published mixed‑methods standards: systematic searches across major databases, dual‑review PRISMA screening and quality appraisal with MMAT, plus theory‑driven coding using frameworks such as UTAUT and Persuasive System Design to surface adoption drivers and UI features (ease‑of‑use, training, facilitating conditions).

Key inclusion rules mirrored recent protocols: focus on interventions that deliver care through digital platforms (web/mobile), measure participant engagement or clinician digital capability, and report empirical outcomes between 2017/18 and mid‑2024 - so peer‑reviewed trials, usability studies and mixed‑method evaluations were prioritized while editorials and gray literature were excluded.

Practical filters came straight from the evidence: studies that documented clear implementation supports (training, IT support, interoperability and single‑login flows) and measurable engagement/retention earned higher weight because barriers like “multiple logins” and poor infrastructure consistently undermined uptake.

The methodology therefore combined the BMC systematic review's readiness themes (performance expectancy, effort expectancy, social influence, facilitating conditions) with the JMIR mixed‑methods protocol's PEO/PEPR screening logic to produce a shortlist of scalable, ethically governed digital health use cases for France; for background on the evidence base and policy context see the systematic review and the mixed‑methods protocol.

Building directly on France 2030 funding and the national push for interoperable, ethically governed AI in care, Owkin's PortrAIt consortium is a concrete step to bring digital pathology into routine oncology: a €33 million, five‑year programme (Bpifrance-backed) that aims to produce at least 15 AI diagnostic tools and a research‑friendly platform to test and deploy them across French cancer centres and pathology labs - think centralized models trained on digitized slides but designed to run in local workflows.

PortrAIt partners include Gustave Roussy, Centre Léon Bérard, Unicancer, Tribun Health and CYPATH, and promises rapid translation from lab to clinic (platform in year one, hospital rollouts within four years); it leverages Owkin's broader consortia work and AI diagnostics capabilities that can reveal tissue‑level patterns and, in some products, deliver results in minutes rather than weeks.

For developers and clinicians mapping PEPR use cases in France, PortrAIt is a live example of public funding, clinical partners and scalable AI converging to democratize precision pathology - see the PortrAIt consortium overview and Owkin's project launch for details.

“Digital pathology-based precision medicine promises to transform how we diagnose and treat diseases, enabling personalized treatment earlier and democratizing access to high-quality care; PortrAIt will empower French hospitals to lead in AI-powered diagnostic tools and aim to make France the global leader in digital pathology-based precision medicine.” - Meriem Sefta, Chief Diagnostics Officer at Owkin

Visible Patient brings surgical planning into the tactile digital age by turning CT or MRI into patient‑specific “virtual livers” that surgeons can rotate, slice and measure to reveal tumours, vascular variants and the post‑resection remnant volume before the first incision - a practical tool for safer hepatectomies, robotic procedures, training and simulation.

Their lab produces 3D reconstructions for cancer staging, cirrhosis, metastases and complex anatomies, supports 4D tumour and organ‑volume follow‑up, and offers exportable models (STL/VTK/GLB/VPZ) plus free viewing software for PC, Mac and XR headsets (note: VP Render is educational, not certified for clinical use).

Clinical interest in immersive preoperative planning is growing - a randomized trial protocol found that VR and 3D printing improve preoperative visualization, underscoring how a tangible, visual model can change surgical decisions and reduce uncertainty at the operating table.

Learn more about Visible Patient's 3D liver reconstructions and the trial comparing VR/3D printing for resection planning.

Application	Details / Outputs
Clinical planning	Visualize tumours, vascular anatomy, estimate post‑op remnant volume
Training & simulation	Augmented/virtual reality, 3D printing, simulator coupling
File formats	STL, VTK, GLB, VPZ (viewing software available)
Evidence	Randomized trial protocol showing VR and 3D printing improve preoperative visualization (Trials Journal)
More info	Visible Patient 3D liver modelling - bespoke 3D reconstructions for liver surgery

Implicity is a clear example of France moving telemonitoring from experiment to mainstream: born out of the ETAPES pilots and recent decrees that defined LATM/LPPR pathways, its universal remote‑monitoring platform aggregates data across cardiac implant makers, adds ML‑driven alerts and has been adopted by 50+ French centres with more than 20,000 locally monitored patients - and crucially it now navigates the reimbursement landscape where some telemonitoring packages carry an organizational tariff of €50 per patient per month.

The practical payoff is tangible: the large EVIDENCE‑RM analysis reported with Implicity found a 26% reduction in mortality and meaningful hospital‑cost savings, which turns a technical workflow into real lives saved and budgets preserved.

For technical, regulatory and tariff details see Implicity telecardiology platform overview and French LPPR telemonitoring codes and guidance.

Metric	Value / Note
Organizational reimbursement (LATM)	€50 per patient per month (LPPR / MTRconsult)
ETAPES physician remuneration	€65 per patient per semester (ETAPES specification)
EVIDENCE‑RM key outcomes	26% reduction in mortality; 17.8% decrease in hospital‑related costs (Heart Rhythm)

“Managing patients with ICDs and CRTs presents considerable challenges, since they are at high risk of hospitalization due to arrhythmias and heart failure... The EVIDENCE‑RM study clearly demonstrates that a universal monitoring solution operating alert‑based remote monitoring can significantly reduce these risks, improving patient outcomes and substantially lowering healthcare costs.” - Dr. Niraj Varma

Collective thinking in clinical decision support and predictive analytics is where France's digital health ambitions meet day‑to‑day care: well‑designed CDSS can surface evidence‑based, patient‑specific recommendations at the point of care, reduce cognitive load and help teams spot deterioration earlier - but only if systems are interoperable, explainable and co‑designed with clinicians.

Reviews and implementation guides highlight familiar barriers - data privacy, EHR integration and clinician acceptance - and practical remedies such as multidisciplinary planning, pilot testing and continuous evaluation; the NHS guide's 5 Rights and 6 i's give a clear playbook for getting the right information to the right person at the right time, while the BMJ review summarises the benefits, limits and ethical safeguards needed for scalable CDSS deployment.

For French hospitals and startups building PEPR‑aligned tools, the lesson is simple: pair predictive models with human oversight, embed them into clinicians' workflows, and make evaluation routine so alerts become trusted helpers instead of noise - imagine an alert that flags an evolving sepsis risk before the next shift starts, turning a blizzard of data into one decisive nudge.

Read the BMJ review on CDSS and the NHS implementation guide for practical design and governance insights.

5 Rights

6 i's

Design framework	Key elements
5 Rights	Right information, Right person, Right format, Right channel, Right time
6 i's	Intelligent, Interpretable, Integrated, Impactful, Interoperable, Inclusive

Iktos, a French AI‑and‑robotics drug‑discovery pioneer, stitches together generative design (Makya), retrosynthesis (Spaya), orchestration (Ilaka) and Iktos Robotics into a fully digitized Design‑Make‑Test‑Analyse loop that can shrink discovery timelines to under 24 months and run six times more parallel projects with the same chemistry team; its Chemspeed‑driven lab executes roughly 100 reactions per day while MT bench® yields thousands of in‑cell events for high‑throughput biology, so in silico ideas become tested molecules at industrial speed.

That industrial conveyor - already deployed across 60+ collaborations and reinforced by an Elsevier partnership to merge Reaxys with Iktos' retrosynthesis - makes Iktos a practical partner for French translational pipelines seeking faster, data‑rich preclinical candidates.

Developers and hospital researchers can explore the platform's technical workflow on Iktos' AI‑driven discovery page and review active programs (MTHFD2, PKMYT1, Amylin receptor, SKP2‑CKS1) on the public pipeline; the so‑what is simple: what used to be months of hand‑crafted chemistry now becomes an orchestrated loop where design, robots and biology rapidly converge on viable candidates.

Target	Therapeutic area	Notes / Stage
MTHFD2	Inflammation & auto‑immune	Hit→Lead→Lead optimization; preclinical candidate nomination expected by 2025
PKMYT1	Oncology	Novel hit series (≈30 nM) generated in <3 months
Amylin Receptor	Obesity / Metabolism	Small‑molecule agonist program; partnership with Cube Biotech
SKP2‑CKS1	Oncology	PPI inhibitor discovery using AI + MTBench cellular assays

“Data is the foundation of AI, and we are very excited to partner with Elsevier. We will combine the strength of Reaxys, a chemistry reaction database with unmatched volume, diversity, and quality, with Iktos' leading edge retrosynthesis AI technology.” - Yann Gaston‑Mathé, CEO, Iktos

Rofim is a Marseille‑born telemedicine platform built to speed diagnosis and tighten multidisciplinary care across France: its integrated modules - tele‑expertise, teleconsultation and e‑RCP with a built‑in DICOM/3D viewer - let city specialists and remote clinicians share cases, imaging and treatment plans from web or mobile, and even convene e‑RCPs of up to 250 professionals to decide complex cases; the platform reports use by roughly 1,600 establishments and 70,000 health professionals with some 1.5 million acts logged, and is positioned to reduce waits and unnecessary transports in medical deserts.

Rofim's interoperability and HDS‑grade hosting (via partners such as Euris/AWS) make document sharing and secure messaging practical for hospitals and networks, while evidence from French pilots supports asynchronous tele‑expertise as a cost‑effective model for prenatal and specialist referrals - see Rofim telemedicine platform, the French Healthcare member profile, and a PLOS case study on asynchronous tele-expertise for evidence.

Metric / Feature	Value / Note
Establishments using Rofim	~1,600 (Rofim telemedicine platform)
Healthcare professionals	~70,000 (Rofim telemedicine platform)
Acts logged	~1,500,000 (Rofim telemedicine platform)
Key modules	Tele‑expertise, Teleconsultation, e‑RCP, DICOM viewer, Messaging

“Our commitment is to reduce diagnostic errors by facilitating the exchange between experts in the medical community. Rofim relies on partners already widely acclaimed, Euris Health Cloud ® and AWS, to bring our digital innovations to the service of our doctors, our caregivers and our patients.” - Emilie MERCADAL, CEO & founder (Euris case study)

Microsoft's Dragon Copilot (branded under the Copilot umbrella) promises to unclog one of French hospitals' biggest bottlenecks - clinical paperwork - by capturing multiparty, multilingual encounters ambiently and converting them into specialty‑specific notes, after‑visit summaries and even referral letters that can flow into EHRs and order modules; the result is practical time reclaimed - vendors suggest gains of up to 20 hours per clinician per week or roughly five minutes saved per encounter - so teams can spend more time at the bedside rather than behind screens.

Built to surface evidence, simplify coding and capture orders, it ties into Microsoft Fabric for analytics while supporting customization, templates and local vocabularies; Microsoft lists France among the countries scheduled for rollout in the second half of 2025 into 2026.

Hospitals planning deployments should pair technical pilots with strict governance and platform hardening so Copilot runs inside a compliant Microsoft 365 footprint.

See the Microsoft Dragon Copilot official overview and Avanade Copilot in Healthcare implementation guidance for implementation and productivity details.

“The DAX technology has allowed them to listen to the patient... And the more that the clinician listens to the patient, the more likely that the care plan will meet the needs of the patient.” - Dr. David Rhew

Dépist&vous brings a patient‑facing triage and virtual‑assistant mindset to cancer prevention in France by turning a short, secure web questionnaire into personalized screening guidance, educational resources, reminders and a directory of local professionals - promising “a few minutes of your time to take care of your health.” The Bordeaux‑based SME positions itself as an anxiety‑reducing gateway to early detection, already marketed with insurers and preparing to link into national tools like Mon espace santé; its simple, independent interface is designed to nudge users toward timely checks and evidence‑based advice that matter in a country where prevention can avert a large share of cancers.

Explore the platform directly at the Dépist&vous cancer prevention platform and read the French healthcare overview for context on how digital prevention services are being integrated into France's e‑health ecosystem.

“What if we were able to prevent one out of every two cases of cancer?” - Dr. Charlotte Berthaut

PEPR Digital Health is France's €60M, France 2030‑backed programme (led by Inserm and Inria) that aims to turn personalised medicine and “digital twins” from research concepts into clinical tools: think multi‑scale models that stitch together genomics, imaging, device data and lifestyle into a single patient representation able to predict disease trajectories from minutes to years.

Focused on 17 funded projects across four priority streams - multi‑scale analysis, socio‑technical challenges of personalised data, cardiovascular and neuroscience applications - the PEPR seeks practical building blocks for hospitals and industry while embedding security, ethics and interoperability at the design stage.

Backed by a national network of universities, CNRS/CEA collaborators and hospital partners, the programme is explicitly designed to accelerate translation (calls for projects and equipment funding are part of the roadmap) and to make France a European leader in AI‑driven prevention and tailored care; read the PEPR launch brief and Inria's programme overview for the official roadmap and scientific priorities.

Item	Detail
Budget	€60M (France 2030)
Leads	Inserm & Inria
Funded projects	17 scientific projects
Priority fields	Cardiovascular diseases; Neurological disorders
Roadmap highlights	Launch 07 Jun 2023; projects start Sept 2023; AMI Mar 2025; CFP Mar 2026

"Digital health is an essential tool for the prevention and treatment of disease." - Professor Didier Samuel, CEO of Inserm

Ethik‑IA in France means turning high‑level principles into hospital‑ready practice: the EU's “trustworthy AI” pillars - human oversight, technical robustness, transparency, privacy and accountability - need to be operationalised alongside national cybersecurity rules so that models never become inscrutable black boxes in the ICU. Practical steps include automating routine compliance (audit trails, policy checklists and secure logging) while keeping clinicians in the loop through human‑in‑the‑loop roles and IRB‑grade review; the CITI Program's modules on AI in human subjects research lay out why ethics review and domain experts must join protocol review to catch bias, consent and privacy gaps early.

For French deployments, pair these governance paths with ANSSI‑aligned cybersecurity hygiene and certification so technical safeguards and legal duties travel together - automation should reduce paperwork without outsourcing responsibility.

The memorable test is simple: if an algorithm flags a patient for urgent intervention, the chain from data to decision must be explainable, auditable and owned by a clinician, not buried in code.

For a philosophical and policy foundation see the Stanford entry on the ethics of AI and robotics, the CITI regulatory modules, and practical ANSSI guidance for healthcare systems in France.

“In this vast ocean of data, there is a frighteningly complete picture of us.”

France's closing playbook is clear: the ANS Doctrine (4th edition) and France 2030 put public power, ethics and industrial scale at the heart of digital health - from a €60M PEPR pushing personalized “digital twins” to the AIS and a €7.5B industry push that anchors innovation on the 20,000 m² PariSanté Campus - so beginners should prioritise low‑risk, standards‑aligned projects that prove clinical value, protect data and keep clinicians in the loop.

The Conseil d'État's seven principles for “trusted public AI” and recent goverment roadmaps stress human primacy, transparency, cybersecurity and frugality, so early adopters must pair pilots with clear performance metrics, CNIL/GDPR and ANS interoperability rules and explicit human‑in‑the‑loop roles; the shortest path to useful skills is pragmatic training in prompts, prompt‑engineering and workplace AI practices.

For a practical start, review the ANS roadmap and the public‑AI doctrine, then build a small, measurable pilot and back it with training - courses such as the AI Essentials for Work bootcamp registration can teach prompt writing and tool use while teams formalise governance under the national doctrine and PEPR priorities.

“Putting digital technology to work for health.”